TrialEffect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia Subjects
Trial details
- Registry ID
- NCT05541939
- Phase
- Phase 2
VOGX
Vogenx, Inc.
Company identity checked against sources
Browse linked trials and recorded changes, or follow this company for updates.
2Trials in this database
2Recorded changes · last 12 months
Partial coverageOnly the trials and history collected so far
Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.
Completion dates · Pro
Which trial dates moved later?
Pro summarizes how far estimated completion dates moved later and counts trials with edits to their main study measures, using the history available here. View Pro features
Included trials
Check company identity source| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Effect of Mizagliflozin on Postprandial Glucose and Insulin in Post-Bariatric Hypoglycemia SubjectsNCT05541939 | VOGX | Phase 2 | Completed | 2023-02-17Actual |
| Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose ExcursionsNCT05721729 | VOGX | Phase 2 | Completed | 2024-05-01Actual |
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
Trial details
- Registry ID
- NCT05721729
- Phase
- Phase 2
Latest recorded trial changes
Effect of Mizagliflozin Repeat Dosing on Adverse Events and Postprandial Glucose Excursions
NCT05721729 · Vogenx, Inc.
Participant count type changed
− Before
Estimated
+ After
Actual
Recruitment status changed
− Before
Active not recruiting
+ After
Completed